Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial
Yanwei Li, Chenguang Li, Chenguang Li, Xiaoliang Zhao et autres
BACKGROUND: To evaluate the efficacy and safety of aumolertinib combined with pemetrexed and carboplatin as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation (exon 19 deletion or exon 21 L858R). METHODS: In phase II …
cn, us (code pays fourni par la source)
5 citations
The Oncologist